Discrepant platelet and plasma von Willebrand factor in von Willebrand disease patients with p.Pro2808Leufs*24. (6th June 2017)

• Record Type: Journal Article
• Authors: Bowman, M. L.; Pluthero, F. G.; Tuttle, A.; Casey, L.; Li, L.; Christensen, H.; Robinson, K. S.; Lillicrap, D.; Kahr, W. H. A.; James, P.
• Is Part Of: Journal of thrombosis and haemostasis. Volume 15:Number 7(2017)
• Page Start: 1403
• Page End: 1411
• Publication Date: 2017-06-06
• Subjects: bleeding -- endothelial cells -- platelets -- von Willebrand disease -- von Willebrand factor; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.13722
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract : Essentials von Willebrand factor (VWF) is synthesized in endothelial cells and platelet precursors. Type 3 patients with Pro2808Leufs*24 have lower bleeding scores than other type 3s. The Pro2808Leufs*24 variant was examined in patient platelets and endothelial cells. Type 3s with this variant contain releaseable VWF, possibly reducing bleeding. Summary: Background: A novel variant, p.Pro2808Leufs*24, in the von Willebrand factor ( VWF ) gene was previously identified in the Canadian von Willebrand disease (VWD) patient population. Clinical observations of type 3 VWD patients with this variant indicate a milder bleeding phenotype compared with other type 3 patients. Objective: To assess the effect of the Pro2808Leufs*24 variant on the molecular pathogenesis of VWD and correlate this with the phenotype observed in patients. Patients/Methods: Phenotypic data from individuals in the Canadian type 3 VWD study were analyzed. VWF expression in platelets and plasma was assessed via immunoblotting. Cellular expression of VWF in platelets and blood outgrowth endothelial cells (BOEC) was examined via immunofluorescence microscopy and biochemical analysis in a type 3 index case and family member with Pro2808Leufs*24. Results: Twenty‐six individuals with the Pro2808Leufs*24 variant (16 type 3 VWD homozygous or compound heterozygous and 10 heterozygous family members) were studied. Bleeding scores were lower in type 3 patients with Pro2808Leufs*24 compared with type 3 patients with other variants, confirming a milder bleeding phenotype. Immunoblotting of platelet lysates detected VWF in the platelets of type 3 patients with Pro2808Leufs*24. Examination of an index case detected VWF within platelets via immunofluorescence microscopy, and in vitro experiments showed that this VWF was released upon platelet activation. Patient BOECs showed decreased VWF synthesis and secretion, although some VWF‐containing granules were observed. Conclusion: Type 3 VWD patients with the Pro2808Leufs*24 have bioavailable platelet‐derived VWF that may produce a milder bleeding phenotype than other type 3s.